While the combination did not affect PBMCs viability (Fig. 7B), it significantly enhanced cell death of CD138+ MM primary cells, confirming the effectiveness of the combinatorial therapy even at the lowest SP2509 concentration (Fig. 7B, C). The gene discussed is SDC1; the disease is Miyoshi myopathy.